Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $3.02, $0.28 better than the analyst estimate of $2.74. Revenue for the quarter came in at $1 billion versus the consensus estimate of $976.13 million.

FY2026 Outlook-

EPS between $11.15 to $11.45 versus consensus $11.09.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.